| Literature DB >> 35591825 |
Marcin Markuszewski1, Magdalena Buszewska-Forajta2, Małgorzata Artymowicz3, Wojciech Połom1, Marek Roslan4, Michał Markuszewski2.
Abstract
Introduction: Surgical oncology strives to remove the primary cancer tumor together with its local lymphatic tissue. One of the techniques improving the staging of lymph nodes is sentinel node biopsy. The most common agent used in SNB is indocyanine green (ICG). Indocyanine green is characterized by its high affinity for human serum albumin (HSA). In practice, the visualization of the sentinel node is enhanced by attaching a relatively large carrier to the ICG molecule. The aim of this study was to investigate whether the covalent linking of ICG to a nanocolloid would extend the time of detection of the dye as it binds to HSA, assessed by fluorescence measurements in vitro. Material and methods: The influence of the molar concentration of ICG on its ability to form a complex with HSA was investigated. The dye luminescence was measured, with an increasing amount of dye in the presence of a constant concentration of HSA. The stability of the ICG:HSA complex was also investigated.Entities:
Keywords: human serum albumin; indocyanine green; sentinel lymph node; urological cancers
Year: 2021 PMID: 35591825 PMCID: PMC9102538 DOI: 10.5114/aoms/113237
Source DB: PubMed Journal: Arch Med Sci ISSN: 1734-1922 Impact factor: 3.707
Volumes of components used for the preparation of ICG : HSA complex solution
| ICG : HSA complex | ICG solution | HSA solution | Purified water [μl] | ||
|---|---|---|---|---|---|
| 5 μg/ml | 2.5 μg/ml | 0.25 μg/ml | 5 μg/ml | ||
| 1 : 1 | – | – | 24.0 | 100 | 76.0 |
| 2.6 : 1 | – | – | 62.4 | 100 | 37.6 |
| 5.3 : 1 | – | 12.5 | – | 100 | 87.5 |
| 7.5 : 1 | – | 17.5 | – | 100 | 82.5 |
| 10.7 : 1 | 12.5 | – | – | 100 | 87.5 |
| 21.4 : 1 | 25.0 | – | – | 100 | 75.0 |
| 32.1 : 1 | 37.5 | – | – | 100 | 62.5 |
| 42.8 : 1 | 50.0 | – | – | 100 | 50.0 |
ICG – indocyanine green, HSA – human serum albumin.
Number of moles of ICG and HSA in every ratio of complex composition
| ICG : HSA ratio | Mass of ICG [ng] | Number of moles of ICG | Mass of HSA [ng] | Number of moles of HSA |
|---|---|---|---|---|
| 1 : 1 | 6.0 | 7.74 × 10–12 | 500 | 7.52 × 10–12 |
| 2.6 : 1 | 15.6 | 20.13 × 10–12 | 500 | 7.52 × 10–12 |
| 5.3 : 1 | 31.3 | 40.32 × 10–12 | 500 | 7.52 × 10–12 |
| 7.5 : 1 | 43.8 | 56.45 × 10–12 | 500 | 7.52 × 10–12 |
| 10.7 : 1 | 62.5 | 80.64 × 10–12 | 500 | 7.52 × 10–12 |
| 21.4 : 1 | 125.0 | 161.29 × 10–12 | 500 | 7.52 × 10–12 |
| 32.1 : 1 | 187.5 | 241.94 × 10–12 | 500 | 7.52 × 10–12 |
| 42.8 : 1 | 250.0 | 322.59 × 10–12 | 500 | 7.52 × 10–12 |
ICG – indocyanine green, HSA – human serum albumin.
Figure 1Peak area as a function of the indocyanine green (ICG) amount obtained for a pure solution of ICG (A), the ICG : HSA complex in solution (B), and cut-off filtrate (C)
Calculation of fluorescence in reference to aqueous solution of pure ICG (A) and aqueous solutions of pure HAS (B)
| A | |||||
|---|---|---|---|---|---|
| Molar ratio of ICG : HSA | Amount of ICG [ng] | ICG | Complex ICG : HSA | ||
| Fluorescence [RFU] | (%) | Fluorescence | (%) | ||
| 1 : 1 | 6.00 | 13 | 100 | 604 | 4646 |
| 5.3 : 1 | 31.25 | 57 | 100 | 396 | 694 |
| 7.5 : 1 | 43.75 | 97 | 100 | 375 | 386 |
| 10.7 : 1 | 62.50 | 146 | 100 | 373 | 255 |
| 21.4 : 1 | 125.00 | 262 | 100 | 426 | 163 |
| 32.1 : 1 | 187.50 | 365 | 100 | 658 | 180 |
| 42.8 : 1 | 250.00 | 435 | 100 | 794 | 183 |
| B | |||||
|---|---|---|---|---|---|
| Molar ratio of ICG : HSA | Amount of HSA [ng] | HSA | Complex ICG : HSA | ||
| Fluorescence [RFU] | (%) | Fluorescence | (%) | ||
| 1 : 1 | 500 | 661 | 100 | 604 | 91 |
| 2.6 : 1 | 500 | 661 | 100 | 501 | 76 |
| 5.3 : 1 | 500 | 661 | 100 | 396 | 60 |
| 7.5 : 1 | 500 | 661 | 100 | 375 | 57 |
| 10.7 : 1 | 500 | 661 | 100 | 373 | 56 |
| 21.4 : 1 | 500 | 661 | 100 | 426 | 64 |
| 32.1 : 1 | 500 | 661 | 100 | 658 | 99 |
| 42.8 : 1 | 500 | 661 | 100 | 794 | 120 |
ICG – indocyanine green, HSA – human serum albumin.